Intravenous versus subcutaneous immunoglobuline therapy in multifocal motor neuropathy
- Conditions
- subcutaneous immunoglobuline therapy Multifocal motor neuropathyIntravenous immunoglobuline therapyDutch: subcutane immunoglobuline Intraveneus immunoglobulineMultifocale motorische neuropathy
- Registration Number
- NL-OMON21709
- Lead Sponsor
- Department of neurologyAcademical Medical Centre, AmsterdamMeibergdreef 9, 1100 DD Amsterdam020-5669111
- Brief Summary
The writing commettee will consist of F. Eftimov, I.N. van Schaik, R. de Haan and M. Vermeulen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
All adult patients (> 18 years) with signs and symptoms consistent with MMN that fulfill the EFNS/PNS criteria for definite MMN and are being treated with IVIg for at least 6 months at regular intervals of at most 6 weeks. Patients have to have stable disease for at least 6 months before inclusion.
1. Use of drugs which are known to cause motor neuropathy;
2. Patient and/or partner is/are unable to administer SCIg at home;
3. Other diseases known to cause neuropathy or to reduce mobility;
4. Diseases known to lead to severe handicap or death at short notice;
5. A known selective IgA deficiency with anti-IgA antibodies;
6. Refusal to give informed consent or withdrawal of previously given permission;
7. Legally incompetent adult
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method